Angiogenic molecular signature in colorectal cancer: Pharmacogenomic implications for the use of antiangiogenic therapies

摘要: In the framework of personalized medicine in antiangiogenesis, we took a translational research approach to explore angiogenic molecular signature advanced CRC patients. As derived from our findings vitro, tumour microenvironment metastases would be different that primary tumours. The mCRC more aggressive phenotype provides some intrinsic resistance hypoxic induction VEGF expression. distinct metastatic "secretome" emerge as potential prognostic markers and alternative intervention targets. identification predictive biomarkers for response bevacizumab-based combination therapy allows informed therapeutic decision patients with mCRC. Platelet-normalized serum circulating baseline levels are significantly lower VEGF-2578AA VEGF-460CC carriers; low-VEGF levels-associated SNPs correlate better clinical outcome TTP. A risk score is calculated considering Kohne low-risk category, DCR achievement any favourable genotype, which renders four groups. High EGF MDC low IL-10, IL-6 IL-8 associated higher likelihood therapy. by summing-up number high-risk factors (below above median MDC, IL-8, respectively) correlates progression survival outcomes, improving single factor’s ability. Exposure reduces increases protective agreement reported roles both cytokines inflammatory angiogenesis mediators colorectal cancer.